The next big approach in Alzheimer’s has been dealt a blow, and there are plenty more tau-targeting contenders.
This week another takeover included a CVR element, confirming a trend that has been gaining traction over the past year.
Behind Global Blood and Novartis, Bluebird leads a pack of biotechs wanting a slice of the sickle cell disease market.
Launch phase is a challenging time for drug developers, so consider the likes of Biohaven, Esperion and, most recently, Urogen, as they brave locked-down markets.
The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.
Using drugs that can cause or exacerbate lung infections to treat the novel coronavirus – what could go wrong?
The fragile X pipeline is strewn with failures, and crunch time is approaching for Zynerba’s cannabinoid.